Gilead’s coronavirus drug trial slowed down due to lack of eligible recruits

| |

February 18, 2020 12:26 am ET

BEIJING: Clinical trials in Wuhan to test the antiviral drug of Gilead Sciences Inc., a promising remedy for the new coronavirus, progress more slowly than expected as the drug manufacturer struggles to recruit qualified patients, which underlines the challenges in the rapid development of medications during outbreaks.

The trials, aimed at evaluating more than 700 patients infected with Wuhan’s coronavirus, have managed to recruit less than 200 people after 10 days.



10 things in technology you should know today, February 18

Filmin Euskaraz, the first Basque streaming channel


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.